Comparative Pharmacology
Head-to-head clinical analysis: MOTRIN versus MOTRIN MIGRAINE PAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOTRIN versus MOTRIN MIGRAINE PAIN.
MOTRIN vs MOTRIN MIGRAINE PAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective COX-1 and COX-2 inhibitor, reducing prostaglandin synthesis.
Reversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis, thereby alleviating pain and inflammation.
Ibuprofen (Motrin) 200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day for acute pain, and 2400 mg/day for chronic use.
Ibuprofen 400 mg orally every 4-6 hours as needed, maximum 1200 mg in 24 hours.
None Documented
None Documented
Terminal elimination half-life approximately 2-4 hours in adults with normal renal function; prolonged in elderly and patients with renal impairment (up to 6-8 hours). No significant accumulation occurs with regular dosing.
2 hours (1.5-2.5 h in adults; prolonged in elderly and renal impairment).
Renal excretion of conjugated metabolites (approximately 70-80% as glucuronide and sulfate conjugates); less than 10% excreted unchanged. Biliary/fecal elimination accounts for about 10-20%.
Renal: 90% (metabolites and unchanged, 10-20% unchanged). Biliary/Fecal: <5%.
Category C
Category C
NSAID Analgesic
NSAID Analgesic